Gamida Cell Ltd. - Ordinary Shares (GMDA): Price and Financial Metrics

Gamida Cell Ltd. - Ordinary Shares (GMDA): $1.73

-0.02 (-1.14%)

POWR Rating

Component Grades













Add GMDA to Watchlist
Sign Up

Industry: Biotech



in industry

GMDA Stock Price Chart Interactive Chart >

Price chart for GMDA

GMDA Price/Volume Stats

Current price $1.73 52-week high $6.84
Prev. close $1.75 52-week low $1.71
Day low $1.71 Volume 73,793
Day high $1.76 Avg. volume 774,934
50-day MA $2.29 Dividend yield N/A
200-day MA $3.13 Market Cap 102.42M

Gamida Cell Ltd. - Ordinary Shares (GMDA) Company Bio

Gamida Cell Ltd. is a clinical stage biopharmaceutical company, which engages in the development of cell therapies that are designed to cure cancer and rare serious hematologic diseases. Its products pipeline include NiCord and NAM-NK. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.

GMDA Latest News Stream

Event/Time News Detail
Loading, please wait...

GMDA Latest Social Stream

Loading social stream, please wait...

View Full GMDA Social Stream

Latest GMDA News From Around the Web

Below are the latest news stories about Gamida Cell Ltd that investors may wish to consider to help them evaluate GMDA as an investment opportunity.

Emergent's (EBS) Q4 Earnings & Sales Beat, CDMO View Cut

Emergent's (EBS) fourth-quarter 2021 earnings and sales beat estimates. The company lowers its guidance for 2022 CDMO services revenues and adjusted net income.

Yahoo | February 25, 2022

BioMarin (BMRN) Q4 Earnings Top Estimates, Sales Fall Y/Y

Biomarin Pharmaceutical's (BMRN) fourth-quarter earnings and sales beat estimates. Stock declines

Yahoo | February 24, 2022

Allogene (ALLO) Beats on Q4 Earnings, Resumes Clinical Studies

Allogene (ALLO) beats earnings estimates for the fourth quarter. However, the stock declines in after-market trading. All clinical studies have been resumed following the removal of clinical hold last month.

Yahoo | February 24, 2022

5 Drug/Biotech Stocks Set to Outpace Q4 Earnings Estimates

Let us take a look at some drug/biotech stocks, EVLO, GMDA, APLS, MRTX and ITOS, which are poised to beat on fourth-quarter earnings.

Yahoo | February 24, 2022

Esperion (ESPR) Q4 Earnings Beat, Product Sales Rise 49%

Esperion Therapeutics (ESPR) reports solid fourth-quarter results, beating estimates for earnings and sales. Stock surges.

Yahoo | February 23, 2022

Read More 'GMDA' Stories Here

GMDA Price Returns

1-mo N/A
3-mo -58.31%
6-mo -31.89%
1-year -73.75%
3-year -65.94%
5-year N/A
YTD -31.89%
2021 -69.73%
2020 95.12%
2019 -56.74%
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6107 seconds.